Recent Updates
Recently added Catalysts
MLTX Negative Sentiment Score: 20/100

MoonLake Immunotherapeutics Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights – MLTX

Key Takeaway: A class action securities lawsuit has been filed against MoonLake Immunotherapeutics alleging fraud. The lawsuit aims to recover losses for investors who were affected by false statements made about the company's drug candidate SLK during the period from March 10, 2024, to September 29, 2025. The complaint claims that the company misrepresented the drug's clinical benefits compared to its competitor BIMZELX. Affected investors have until December 15, 2025, to request lead plaintiff status in the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • The lawsuit alleges securities fraud committed by the company's management.
  • Claims include false statements regarding the drug candidate SLK's efficacy and superiority.
  • Investors are facing potential financial losses due to the disclosed legal issues.
  • Concerns about the clinical benefit of SLK compared to existing treatments.

Full Press Release Details

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ("MoonLake" or the "Company") (NASDAQ: MLTX) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of MoonLake investors who were adversely affected by alleged securities fraud between March 10, 2024 and September 29, 2025. Follow the link below to get more information and be contacted by a member of our team:
MLTX investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) It's sole drug candidate, SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK’s distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK’s distinct Nanobody structure supposed increased tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK’s purported superiority to monoclonal antibodies.
WHAT'S NEXT? If you suffered a loss in MoonLake during the relevant time frame, you have until December 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor

Tags

Frequently Asked Questions

What is the lawsuit against MoonLake Immunotherapeutics about?

The lawsuit is about alleged securities fraud affecting MoonLake investors from March 10, 2024, to September 29, 2025.

What are the main allegations in the class action lawsuit?

The allegations include false statements regarding MoonLake's drug candidate SLK compared to BIMZELX.

What is the deadline to request lead plaintiff status?

You have until December 15, 2025, to request lead plaintiff status in the lawsuit.

Will it cost me anything to participate in the lawsuit?

There's no cost to participate; class members may receive compensation without out-of-pocket fees.

Why should I choose Levi & Korsinsky for this case?

Levi & Korsinsky has extensive experience in securities litigation and a successful track record.

Last updated: Nov 25, 2025